Clinical trial · Interventional
Surgicel® Fibrillar for Delayed Bleeding After ESD
Surgicel® (Fibrillar) for Preventing Delayed Bleeding After ESD in Stomach: A Prospective Randomized Study
NCT01758965CI-TRIAL-00014494completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Neoplasm of Stomach | Benign Gastric Neoplasm | ALIAS | 0.90 |
| Malignant Neoplasm of Stomach | Malignant Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| H2RA and surgicel | Other | — | UNRESOLVED |
| PPI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- combination therapy of H2RA and surgicel
- description
- H2RA and surgicel
- interventionNames
- Other: H2RA and surgicel
- type
- EXPERIMENTAL
- label
- Monotherapy of PPI
- description
- PPI
- interventionNames
- Other: PPI
Primary outcomes (1)
- measure
- Delayed bleeding rate after ESD
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * ESD for gastric dysplasia or early gastric cancer Exclusion Criteria: * Coagulopathy: liver cirrhosis, thrombocytopenia * Anti-platelet agents
References
Publications (0)
Data not yet available
No reference posted for this study.